期刊文献+

吡格列酮联合诺和灵30R治疗2型糖尿病肾病的体会 被引量:3

下载PDF
导出
摘要 目的应用吡格列酮联合诺和灵30R胰岛素与单用诺和灵30R胰岛素治疗的糖尿病肾病进行回顾性分析,观察两种治疗对尿白蛋白排泄率、血糖、血脂等指标的影响。方法对诊治的117例早期糖尿病肾病患者为观察对象,据用药不同分为两组:联合治疗组62例,应用吡格列酮联合诺和灵30R胰岛素;单药治疗组55例,单用诺和灵30R胰岛素治疗。观察时间均为12周。观察治疗前后两组尿白蛋白排泄率(UAER)、肝肾功能、糖化血红蛋白(HbAlc)、空腹血糖(FBG)、餐后血糖(PBG)、胆固醇(TC)、甘油三酯(TG)的变化。结果两组治疗后空腹血糖、餐后血糖、糖化血红蛋白、胆固醇、甘油三酯水平均比治疗前有显著下降(P<0.05或P<0.001),其中甘油三酯水平联合治疗组下降幅度优于单药治疗组(P<0.05)。联合治疗组尿白蛋白排泄率亦有显著改善,与基线及单药治疗组相比差异有显著性(P<0.01)。两组治疗前后肝肾功能无显著性差异(P>0.05)。结论吡格列酮联合诺和灵30R胰岛素治疗糖尿病肾病在降低糖化血红蛋白的同时,显著降低尿白蛋白排泄率,同时可改善甘油三酯水平,优于单用诺和灵30R胰岛素治疗。
出处 《中国临床医生杂志》 2011年第11期35-37,共3页 Chinese Journal For Clinicians
  • 相关文献

参考文献9

  • 1王海燕主编..肾脏病学 第2版[M].北京:人民卫生出版社,1987:1736.
  • 2徐焕宇,王战建.噻唑烷二酮类药物对糖尿病肾脏的保护作用[J].国外医学(内分泌学分册),2005,25(4):268-270. 被引量:1
  • 3Day C. Thiazolidinediones: A new class of antidiabetic drugs [J]. Diabet Med, 1999, 16 (3):179-192. 被引量:1
  • 4Uehara G, Suzuki G, Toyoda M, et al. Glomerular expression of platelet-derived growth factor PDGF-A, B chain and PDGF re- ceptor-a, 13 in diabetic nephropathy [ J ] . Clin Exp Nephrol, 2004, 8:36 -42 . 被引量:1
  • 5Yokio A, Shinji K, Noriyuki O, et al, Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB- binding protein and regulates growth factor-induced common pos- treceptor singnal in vascular smooth muscle cell [ J ] . Circulation, 2002,105: 2893 - 2898. 被引量:1
  • 6Frser D, Wakefild L, Phillips A, et al. Independent regulation of transforming growth factor-betal, transcription and translation by glueose and platelet-derived growth factor[ J]. Am J Pathol, 2002,161 : 1039 - 1049. 被引量:1
  • 7Kunogi Y. Mesangia cell proliferation inhibitors for the treatment of proliferative glomerular disease [ J ]. Med Res Rev, 2003,23 : 15 -31. 被引量:1
  • 8Buckingham R E, AI-Barazanji K A, Toseland C D, et al . Peroxisome proliferator activated reeeptor-r agonist, rosigcitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats[ J]. Diabetes, 1998, 47:1326 - 1334. 被引量:1
  • 9Yoshimoto T, Naruse M, Nishikawa M, et al . Antihypertensive and vasculo and renoprotective effects of pioglitazone in genetically obese diabetic rats [J]. Am J physiol, 1997, 272:E989 - E996. 被引量:1

二级参考文献11

  • 1Isshiki K, Haneda M, Koya D, et al. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes,2000,49:1022-1032. 被引量:1
  • 2Verrier E, Wang L, Wadham C, et al. PPARgamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacylglycerol kinase. Circ Res,2004,94:1515-1522. 被引量:1
  • 3Reilly GM, Oates JC, Cook JA, et al. Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor-gamma agonists. J Immunol,2000,164:1498-1504. 被引量:1
  • 4McCarthy KJ, Routh RE, Shaw W, et al. Troglitazone halts diabetic glomerulosclemsis by blockade of mesangial expansion. Kidney Int,2000,58: 2341-2350. 被引量:1
  • 5Ma LJ, Marcantoni C,Linton MF, et al. Peroxisome proliferator-activated receptor-γ agonist troglitazone protects agaist nondiabetic glomerulosclerosis in rats. Kidney Int,2001,59:1899-1910. 被引量:1
  • 6Onozaki A, Midorikawa S, Sanada H, et al. Rapid change of glucose concentration promotes mesangial cell proliferation via VEGF: inhibitory effects of thiazolidinedione. Biochem Biophys Res Commun, 2004,317:24-29. 被引量:1
  • 7Ghosh SS, Gehr TW, Ghosh S, et al. PPAR-γ ligand attenuates PDGFinduced mesangial cell proliferation: role of MAP kinase. Kidney Int,2003,64: 52-62. 被引量:1
  • 8Yatagai T, Nakamura T, Nagasaka S, et al. Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects. Diabetes Res Clin Pract, 2004,63:19-26. 被引量:1
  • 9Ohta MY, Nagai Y, Takamura T, et al. Inhibitory effect of troglitazone on tumor necrosis factor alpha-induced expression of monocyte chemoattractant protein-1 in human messangial cells. Metabolism,2000,49:163-166. 被引量:1
  • 10Florkowski CM. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones. Am J Cardiovasc Drugs,2002,2:15-21. 被引量:1

同被引文献31

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部